Compare TK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | ABCL |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 910.0M |
| IPO Year | 1995 | 2020 |
| Metric | TK | ABCL |
|---|---|---|
| Price | $12.21 | $3.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 656.7K | ★ 3.1M |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | ★ 16.38% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.59 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $5.65 | $1.89 |
| 52 Week High | $13.76 | $6.52 |
| Indicator | TK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 48.73 |
| Support Level | $9.11 | $3.37 |
| Resistance Level | N/A | $3.57 |
| Average True Range (ATR) | 0.52 | 0.22 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 38.96 | 54.02 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.